Anixa Biosciences (NASDAQ:ANIX) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Anixa Biosciences (NASDAQ:ANIX) from a hold rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.

ANIX has been the subject of a number of other reports. Weiss Ratings upgraded Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. HC Wainwright lowered their price objective on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, September 22nd. Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a research note on Tuesday, October 6th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.00.

Anixa Biosciences Stock Down 4.2%

NASDAQ:ANIX opened at $2.99 on Friday. The firm has a market cap of $103.94 million, a PE ratio of -9.34 and a beta of 0.47. Anixa Biosciences has a 12 month low of $2.32 and a 12 month high of $5.46. The company’s 50-day moving average price is $2.96 and its two-hundred day moving average price is $2.97.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). On average, research analysts expect that Anixa Biosciences will post -0.31 EPS for the current fiscal year.

Insider Activity at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis Titterton, Jr. bought 49,036 shares of the company’s stock in a transaction on Wednesday, September 23rd. The stock was bought at an average price of $2.69 per share, for a total transaction of $131,906.84. Following the transaction, the director owned 1,046,003 shares of the company’s stock, valued at approximately $2,813,748.07. The trade was a 4.92% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have acquired 105,536 shares of company stock worth $291,587. Insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

Large investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Anixa Biosciences in the second quarter worth $559,000. GSA Capital Partners LLP acquired a new position in shares of Anixa Biosciences in the 2nd quarter valued at $329,000. CoreCap Advisors LLC grew its holdings in shares of Anixa Biosciences by 19.2% in the 3rd quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock valued at $182,000 after buying an additional 10,000 shares during the period. Renaissance Technologies LLC increased its position in shares of Anixa Biosciences by 13.6% in the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after buying an additional 7,300 shares in the last quarter. Finally, Kestra Advisory Services LLC increased its position in shares of Anixa Biosciences by 96.2% in the 1st quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after buying an additional 25,000 shares in the last quarter. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company’s programs are designed to use the immune system to identify and attack disease-associated targets.

Anixa’s oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.